Aquestive Therapeutics, Inc. (AQST) Form 8-K — Oct 14, 2026
Aquestive Therapeutics entered an exclusive U.S. license agreement with Eton Pharmaceuticals for LIBERVANT (diazepam) buccal film, receiving a $10.0 million upfront fee with up to $47.5 million in additional milestone payments plus mid-teens royalties on net sales. Aquestive will remain the exclusive manufacturer under a 20-year supply agreement, preserving CDMO economics on top of royalty income. LIBERVANT has tentative FDA approval and is expected to be fully approved for patients 12 and older after VALTOCO's orphan exclusivity expires January 10, 2027, with an anticipated April 2027 launch.
Key figures
- Pdufa date
- March 29, 2027
- Royalty rate
- mid-teens percentage of annual net sales
- Max milestones
- $47.5 million
- Patent protection
- extends into 2038
- Anticipated launch
- April 2027
- Upfront license fee
- $10.0 million
- Supply agreement term
- 20 years initial term
- Us seizure rescue market
- exceeds $450 million annually
- Valtoco exclusivity expiry
- January 10, 2027
- Commercial sales milestones
- up to $35.0 million
- Ages 6 11 approval milestone
- $2.5 million
- First commercial sale milestone
- $10.0 million (reduced to $5.0 million without FDA approval for ages 2-5)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.